Progress in ubiquitin-specific protease 1 of tumors

doi:10.16352/j.issn.1001-6325.2026.09.1277

Abstract

Abstract: Ubiquitin-specific protease 1 (USP1) is an important member of the deubiquitinase family. It participates in biological processes such as DNA damage repair by regulating the stability of key proteins. USP1 is abnormally expressed in various tumors, and its expression level is closely related to tumor initiation, progression, metastasis and prognosis. Abnormal USP1 expression in multiple cancer cell types regulates cancer cell development through affecting biological processes including DNA damage repair, epithelial-mesenchymal transition, autophagy, cell cycle and mitochondrial fission. In-depth analysis of USP1 function and mechanism involved in various cancer cells provides a theoretical basis for diagnosis, prevention and treatment, as well as the development of USP1-targeted drugs.

Key words: ubiquitin-specific protease 1, cancer, chemoresistance, DNA damage

CLC Number:

LIU Lindi, LIU Xuyan, LYU Qingjie. Progress in ubiquitin-specific protease 1 of tumors[J]. Basic & Clinical Medicine, 2026, 46(9): 1277-1281.

References

[1] Zhao Y, Xue C, Xie Z, et al. Comprehensive analysis of ubiquitin-specific protease 1 reveals its importance in hepatocellular carcinoma[J]. Cell Prolif, 2020,10:e12908. doi: 10.1111/cpr.12908.
[2] Fujiwara T, Saito A, Suzuki M, et al. Identification and chromosomal assignment of USP1, a novel gene encoding a human ubiquitin-specific protease[J]. Genomics, 1998,54:155-158. doi: 10.1006/geno.1998.5554.
[3] Wang L, Hu T, Shen Z, et al. Inhibition of USP1 activates er stress through ubi-protein aggregation to induce autophagy and apoptosis in HCC[J]. Cell Death Dis, 2022,13:951. doi: 10.1038/s41419-022-05341-3.
[4] Bian S, Ni W, Zhou L, et al. Ubiquitin-specific protease 1 facilitates hepatocellular carcinoma progression by modulating mitochondrial fission and metabolic reprogramming via cyclin-dependent kinase 5 stabilization[J]. Cell Death Differ, 2024,31:1202-1218. doi: 10.1038/s41418-024-01342-1.
[5] Wu Z, Li C, Zhang S, et al. High interstitial fluid pressure enhances USP1-dependent KIF11 protein stability to promote hepatocellular carcinoma progression[J]. J Transl Med, 2025,23:66. doi: 10.1186/s12967-025-06124-y.
[6] Ma A, Tang M, Zhang L, et al. USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis[J]. Oncogene, 2019,38:2405-2419. doi: 10.1038/s41388-018-0590-8.
[7] Su Y, Du Y, He W. USP1-mediated deubiquitination of KDM1A promotes the malignant progression of triple-negative breast cancer[J]. J Biochem Mol Toxicol, 2024,38:e23864. doi: 10.1002/jbt.23864.
[8] Li JT, Li KY, Su Y, et al. Diet high in branched-chain amino acid promotes pdac development by USP1-mediated BCAT2 stabilization[J]. Natl Sci Rev, 2022,9:nwab212. doi: 10.1093/nsr/nwab212.
[9] Li L, Fan Z, Liu M, et al. USP1 promotes pancreatic cancer progression and autophagy by deubiquitinating ATG14[J]. J Biol Chem, 2025,301:108190. doi: 10.1016/j.jbc.2025.108190.
[10] Sun Y, Sha B, Huang W, et al. Ml323, a USP1 inhibitor triggers cell cycle arrest, apoptosis and autophagy in esophageal squamous cell carcinoma cells[J]. Apoptosis, 2022,27:545-560. doi: 10.1007/s10495-022-01736-x.
[11] Tang X, Weng R, Guo G, et al. USP10 regulates macrophage inflammation responses via stabilizing nemo in lps-induced sepsis[J]. Inflamm Res, 2023,72:1621-1632. doi: 10.1007/s00011-023-01768-2.
[12] Zhang DY, Zhu Y, Wu Q, et al. USP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation[J]. Cell Death Dis, 2023,14:669. doi: 10.1038/s41419-023-06172-6.
[13] Lee JK, Chang N, Yoon Y, et al. USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance[J]. Neuro Oncol, 2016,18:37-47. doi: 10.1093/neuonc/nov091.
[14] Das DS, Das A, Ray A, et al. Blockade of deubiquitylat-ing enzyme USP1 inhibits DNA repair and triggers apoptosis in multiple myeloma cells[J]. Clin Cancer Res, 2017,23:4280-4289. doi: 10.1158/1078-0432.CCR-16-2692.
[15] Simoneau A, Engel JL, Bandi M, et al. Ubiquitinated pcna drives USP1 synthetic lethality in cancer[J]. Mol Cancer Ther, 2023,22:215-226. doi: 10.1158/1535-7163.MCT-22-0409.
[16] da Costa AA, Somuncu O, Ravindranathan R, et al. Single-stranded DNA gap accumulation is a functional biomarker for USP1 inhibitor sensitivity[J]. Cancer Res, 2024,84:3435-3446. doi: 10.1158/0008-5472.CAN-23-4007.
[17] Nespolo A, Stefenatti L, Pellarin I, et al. USP1 deubiquitinates parp1 to regulate its trapping and parylation activity[J]. Sci Adv, 2024,10:eadp6567. doi: 10.1126/sciadv.adp6567I.
[18] Cadzow L, Brenneman J, Tobin E, et al. The USP1 inhibitor KSP-4279 overcomes parp inhibitor resistance in homologous recombination-deficient tumors[J]. Cancer Res, 2024,84:3419-3434. doi: 10.1158/0008-5472.CAN-24-0293.
[19] Tyagi A, Kaushal K, Chandrasekaran AP, et al. Crispr/cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells[J]. Theranostics, 2022,12:5949-5970. doi: 10.7150/thno.72826.
[20] Woo SM, Kim S, Seo SU, et al. Inhibition of USP1 enhances anticancer drugs-induced cancer cell death through downregulation of survivin and Mir-216a-5p-mediated upregulation of DR5[J]. Cell Death Dis, 2022,13:821. doi: 10.1038/s41419-022-05271-0.
[21] Mallard HJ, Wan S, Nidhi P, et al. USP1 expression driven by ews::Fli1 transcription factor stabilizes survivin and mitigates replication stress in ewing sarcoma[J]. Mol Cancer Res,2023,21:1186-1204. doi: 10.1158/1541-7786.MCR-23-0323.
[22] Lu Z, Zhang Z, Yang M, et al. Ubiquitin-specific protease 1 inhibition sensitizes hepatocellular carcinoma cells to doxorubicin by ubiquitinated proliferating cell nuclear antigen-mediated attenuation of stemness[J]. Anticancer Drugs, 2022,33:622-631. doi: 10.1097/CAD.0000000000001311.
[23] Chen Z, Ma Y, Guo Z, et al. Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit[J]. Ann Hepatol, 2022,27:100669. doi: 10.1016/j.aohep.2022.100669.
[24] Li XY, Wu JC, Liu P, et al. Inhibition of USP1 reverses the chemotherapy resistance through destabilization of max in the relapsed/refractory b-cell lymphoma[J]. Leukemia, 2023,37:164-177. doi: 10.1038/s41375-022-01747-2.